Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 501

Sort by

Sort Order Select

Journal Articles

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Matthew C. Foster, Barbara Savoldo, Winnie Lau, Clio Rubinos, Natalie Grover, Paul Armistead, James Coghill, Robert S. Hagan, Kaitlin Morrison, Faith Brianne Buchanan, Catherine Cheng, Spencer Laing, Anastasia Ivanova, John West, Aaron Foster, Jonathan Serody, Gianpietro Dotti

Blood (2021) 137 (23): 3306–3309.

https://doi.org/10.1182/blood.2021010784

Published: 2021

Includes: Supplemental data

Journal Articles

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Rebecca A. Gardner, Francesco Ceppi, Julie Rivers, Colleen Annesley, Corinne Summers, Agne Taraseviciute, Juliane Gust, Kasey J. Leger, Katherine Tarlock, Todd M. Cooper, Olivia C. Finney, Hannah Brakke, Daniel H. Li, Julie R. Park, Michael C. Jensen

Blood (2019) 134 (24): 2149–2158.

https://doi.org/10.1182/blood.2019001463

Published: 2019

Includes: Supplemental data

Journal Articles

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk (HR/IR) First Relapse of B-Acute Lymphoblastic Leukemia (B-ALL) in Children and Adolescents/Young Adults (AYAs) Demonstrates Superior Efficacy and Tolerability of Blinatumomab: A Report from Children's Oncology Group Study AALL1331

Patrick A. Brown, MD, Lingyun Ji, PhD, Xinxin Xu, MS, Meenakshi Devidas, PhD, Laura Hogan, MD, Michael J. Borowitz, MD PhD, Elizabeth A. Raetz, MD, Gerhard Zugmaier, Elad Sharon, MD MPH, Lia Gore, MD, James A. Whitlock, MD, Michael A. Pulsipher, MD, Stephen P. Hunger, MD, Mignon L. Loh, MD

Blood (2019) 134 (Supplement_2): LBA-1.

https://doi.org/10.1182/blood-2019-132435

Published: 2019

Journal Articles

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Blood (2019) 134 (Supplement_1): 4435.

https://doi.org/10.1182/blood-2019-126104

Published: 2019

Journal Articles

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Ryan J Caddell, PharmD, BCOP, Hayder Saeed, MD, Rebecca Nelson, PharmD, BCOP, Leidy Isenalumhe, MD, Julio Chavez, Celeste Bello, MD, Javier Pinilla Ibarz, MD PhD, Lubomir Sokol, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5292.

https://doi.org/10.1182/blood-2019-128435

Published: 2019

Journal Articles

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Jakub Svoboda, MD, Hatcher J. Ballard, BS, Elise A. Chong, MD, Meredith I LaRose, MD, Steven M. Bair, MD, Esin C. Namoglu, B.S., Mitchell E. Hughes, PharmD, Sunita Dwivedy Nasta, MD, Daniel J. Landsburg, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elizabeth Weber, BSN, RN, Chase Walling, BS, Marco Ruella, MD, Noelle V. Frey, MD, David L. Porter, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 1606.

https://doi.org/10.1182/blood-2019-131482

Published: 2019

Journal Articles

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1603.

https://doi.org/10.1182/blood-2019-125162

Published: 2019

Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Blood (2019) 134 (Supplement_1): 1609.

https://doi.org/10.1182/blood-2019-131499

Published: 2019

Journal Articles

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

Matthew Frigault, MD MSc, Megan Cartwright, PhD, Krista Marcello, BA, Timothy A Quill, PhD, Daniel J. DeAngelo, MD PhD, Ilene Galinsky, Shilpa Paul, PharmD, Jae H. Park, MD

Blood (2019) 134 (Supplement_1): 2199.

https://doi.org/10.1182/blood-2019-131533

Published: 2019

Journal Articles

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Barbara Jeker, Sarah Farag, Urban Novak, Ulrike Bacher, Behrouz Mansouri Taleghani, Qiyu Li, Thomas Pabst, MD

Blood (2019) 134 (Supplement_1): 1963.

https://doi.org/10.1182/blood-2019-127848

Published: 2019

Journal Articles

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

David A Sallman, MD, Jason B. Brayer, PhDMD, Xavier Poire, Violaine Havelange, Ahmad Awada, MD PhD, Philippe Lewalle, Kunle Odunsi, MD, Eunice S. Wang, MD, Caroline Lonez, PhD, Thomas Lequertier, Erik Alcantar-Orozco, MD, Nathalie Braun, Anne Flament, MD, Ine Moors, MD, Tessa Kerre

Blood (2019) 134 (Supplement_1): 3826.

https://doi.org/10.1182/blood-2019-128020

Published: 2019

Journal Articles

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Erica Brivio, MD, Raoull Hoogendijk, MSc, Christophe Chantrain, MD PhD, Fanny Rialland, MD, Audrey Contet, Sarah Elitzur, MD, Luciano Dalla-Pozza, MBBS FRACP, Krisztian Kallay, MD, Chi Kong Li, MBBS,MD, Motohiro Kato, MD PhD, Inna V Markova, Dr., Kjeld Schmiegelow, Professor MD DMSc., Nicole Bodmer, Rob Pieters, MDPhDMSc, Christian Michel Zwaan, MD PhD

Blood (2019) 134 (Supplement_1): 3890.

https://doi.org/10.1182/blood-2019-126472

Published: 2019

Journal Articles

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Michelle J. Cox, Charles J. Kuhlmann, Rosalie M. Sterner, Reona Sakemura, MD PhD, Sutapa Sinha, PhD, Raphael Mwangi, MS, Nancy Scott, MS, Mehrdad Hefazi, MD, Omar Ahmed, Dale Chappell, Cameron Durrant, Claudia Manriquez Roman, Kendall J. Schick, Erin E. Tapper, Paulina Horvei, MD, Michael W. Ruff, MD, Sameer A. Parikh, MD, Neil E. Kay, MD, Saad S. Kenderian, MD

Blood (2019) 134 (Supplement_1): 3868.

https://doi.org/10.1182/blood-2019-129349

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Daria Gaut, MD, Kevin Tang, BS, BA, Myung Sim, PhD, Tuyen Duong, Joshua Sasine, MD PhD, Patricia A. Young, MD

Blood (2019) 134 (Supplement_1): 4109.

https://doi.org/10.1182/blood-2019-122195

Published: 2019

Journal Articles

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

James K McCloskey, MD, Joelle Gagnon, NP, Tara McCabe, FNP-C, MSN, RN, BSN, Jocelyn Charlon, MS, AGPCNP-BC, Shuqi Wang, MSc, Ruzong Fan, Stuart L. Goldberg, MD, Jamie Koprivnikar, MD

Blood (2019) 134 (Supplement_1): 3812.

https://doi.org/10.1182/blood-2019-131838

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Caixia Li, Changfeng Zhang, PhD, Ying Zhang, Xiaoyan Lou, Jinfang Zhang, Jia Chen, MD, Xiaochen Chen, Liqing Kang, Jin Zhou, Xiangping Zong, Zhen Yang, Jiaqi Li, Wei Qi, Lei Yu, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 4097.

https://doi.org/10.1182/blood-2019-127928

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Harbani Malik, PhD, Ben Buelow, MD PhD, Udaya Rangaswamy, PhD, Aarti Balasubramani, Andrew Boudreau, Kevin Dang, Laura Davison, PhD, Shelley Force Aldred, Katherine Marie Harris, MD, Suhasini Iyer, PhD, Brett Jorgensen, PhD, Duy Pham, MBA, Kirthana Prabhakar, Ute Schellenberger, PhD, Harshad Ugamraj, Nathan Trinklein, PhD, Wim Van Schooten, PhD

Blood (2019) 134 (Supplement_1): 4070.

https://doi.org/10.1182/blood-2019-123226

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy

Phase 1 Trial of the Safety and Efficacy of Fully Human Anti-Bcma CAR T Cells in Relapsed/Refractory Multiple Myeloma

Toxicity of a Modified Peg-Asparaginase-Based SMILE Regimen Is Comparable to L-Asparaginase-Based SMILE in a Non-Asian Population

Use of Bendamustine for Lymphodepletion before Tisagenlecleucel (anti-CD19 CAR T cells) for Aggressive B-Cell Lymphomas

Impact and Safety of Chimeric Antigen Receptor T Cell Therapy in Vulnerable Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations

A Randomized Evaluation of Vinorelbine Versus Gemcitabine Chemotherapy Mobilization of Stem Cells in Myeloma Patients

Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients

A Retrospective Study on Inotuzumab Ozogamicin in Infants and Young Children with Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)

Improved Anti-Tumor Response of Chimeric Antigen Receptor T Cell (CART) Therapy after GM-CSF Inhibition Is Mechanistically Supported By a Novel Direct Interaction of GM-CSF with Activated Carts

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Granulocyte Colony-Stimulating Factor (G-CSF) Interactions with Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma

Blinatumomab in Combination with Tyrosine Kinase Inhibitors Safely and Effectively Induces Rapid, Deep, and Durable Molecular Responses in Relapsed and Refractory Philadelphia Positive Acute Leukemias

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Cellular Kinetics of CD19 Chimeric Antigen Receptor T Cells in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

TNB-486, a Novel Fully Human Bispecific CD19 x CD3 Antibody That Kills CD19-Positive Tumor Cells with Minimal Cytokine Secretion

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only